Breaking Finance News

Zacks Investment Research upgraded Intrexon Corp (NYSE:XON) to Hold in a report released today.

Just yesterday Intrexon Corp (NYSE:XON) traded -3.19% lower at $26.03. Intrexon Corp’s 50-day moving average is $27.36 and its 200-day moving average is $27.71. The last stock price is down -6.78% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 1,092,518 shares of XON traded hands, down from an average trading volume of 1,431,350

Zacks Investment Research has upgraded Intrexon Corp (NYSE:XON) to Hold in a report released on 10/17/2016.

Recent Performance Chart

Intrexon Corp (NYSE:XON)

Intrexon Corp has 52 week low of $18.52 and a 52 week high of $43.76 and has a market capitalization of $0.

In addition to Zacks Investment Research reporting its stock price target, a total of 7 brokerages have issued a ratings update on the company. The average stock price target is $53.00 with 2 brokerages rating the stock a strong buy, 2 brokerages rating the stock a buy, 3 brokerages rating the stock a hold, 0 brokerages rating the stock a underperform, and finally 0 brokerages rating the stock a sell.

Brief Synopsis On Intrexon Corp (NYSE:XON)

Intrexon Corporation (Intrexon) forms collaborations to create biologically based products and processes using synthetic biology. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components. The Company's synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells and optimize for desired results at an industrial scale. Its technologies combine the principles of precision engineering, statistical modeling, automation and production at an industrial scale. The Company's technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing, or LEAP, and ActoBiotics platform.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *